Clinical trial
Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary…
NCT00003526 · Burzynski Research Institute, Other · Terminated
Key facts
| NCT number | NCT00003526 |
|---|---|
| Title | Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin |
| Official title | Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Adenocarcinoma of Unknown Primary |
| Lead sponsor | Burzynski Research Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Unknown Primary Carcinoma |
| Intervention type | Drug |
| Interventions | Antineoplaston therapy (Atengenal + Astugenal) |
| Enrollment | 8 |
| Start date | Mar 18, 1996 |
| Primary completion | Feb 2, 2005 |
| Completion | Feb 2, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 17, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: